Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in All-Cash Deal at $14.00 Per Share

summarizeSummary

Ventyx Biosciences announced a definitive agreement to be acquired by Eli Lilly and Company for approximately $1.2 billion, or $14.00 per share in cash, representing a substantial premium for shareholders.

check_boxKey Events

• Definitive Merger Agreement

  Ventyx Biosciences, Inc. has entered into an Agreement and Plan of Merger with Eli Lilly and Company, under which Eli Lilly will acquire Ventyx.

• All-Cash Acquisition Price

  Eli Lilly will acquire all outstanding shares of Ventyx common stock for $14.00 per share in cash, totaling an aggregate equity value of approximately $1.2 billion.

• Significant Premium Offered

  The purchase price represents a premium of approximately 62% to Ventyx's 30-day volume-weighted average trading price as of January 5, 2026.

• Insider Support for Transaction

  Directors, officers, and entities affiliated with New Science Ventures, collectively owning approximately 10% of Ventyx's outstanding common stock, have signed voting and support agreements in favor of the merger.

auto_awesomeAnalysis

Ventyx Biosciences has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for approximately $1.2 billion in an all-cash transaction. This represents a significant premium for Ventyx shareholders, with an offer price of $14.00 per share compared to the current stock price of $13.74. The acquisition is strategically important for Eli Lilly, expanding its pipeline in inflammatory-mediated diseases with Ventyx's NLRP3 inhibitors and other small molecule therapeutics. The deal is supported by Ventyx's directors, officers, and a key institutional investor, collectively owning about 10% of outstanding common stock, which increases the certainty of the transaction closing. The acquisition is subject to customary closing conditions, including Ventyx stockholder and regulatory approvals, and is expected to close in the first half of 2026.